Latest filing published 18 Aug 2026 for Pacira BioSciences, Inc., €61k. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Jonathan Slonin is a declared insider of Pacira BioSciences, Inc. (senior executive), with filings sourced from SEC (Form 4). Between 3 August 2021 and 17 August 2026, the trades on record add up to 21 filings.
Sales make up the whole of the open-market record (8 sales, €447k). Other entries cover 12 share grants and 1 option exercise. So far in 2026, the count stands at no purchases and 2 sales.
The newest entry dates from 18 August 2026: an open-market sale of €61k, in Pacira BioSciences, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. Section 16 rules allow two business days to file each Form 4. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
21 of 21 declarations